Onset Therapeutics LLC, a specialty pharmaceutical company focused in dermatology, today announced that the Company’s recent growth and future opportunities have facilitated an expansion of its field sales organization to cover more than twenty-five additional major metropolitan areas. The expansion is a direct result of the success of two recently launched dermatologic products and the Company’s robust product pipeline that includes both near term and mid-term product candidates.
“The successful launch of our two latest products in 2009 has enabled us to continue to expand the breadth and depth of our sales force to create our first nationwide presence”
The Company has significant internal product development and manufacturing capabilities which have led to the development of the Company’s proprietary Delevo® Foam technology. Delevo® Foam is an emollient, non-alcohol based foam vehicle that is incorporated into a number of the Company’s current and future product offerings, including the recently launched products, Hylatopic® and BenzEFoam™.
Hylatopic® Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis, received FDA clearance in the spring of 2009 and was launched by the Company in July 2009.